Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL162590 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL6553020 | 0.95 | CA1 (0.45) | — | |
| Fumaric Acid SCHEMBL21815723 | 0.95 | CA1 (0.45) | — | |
| Fumaric Acid SCHEMBL6553031 | 0.95 | CA1 (0.45) | — | |
| Fumaric Acid SCHEMBL23828619 | 0.91 | — | — | |
| Fumaric Acid SCHEMBL20610493 | 0.91 | CA1 (0.43) | — | |
| Fumaric Acid SCHEMBL187682 | 0.91 | — | — | |
| Fumaric Acid SCHEMBL20657014 | 0.91 | CA1 (0.43) | — | |
| Fumaric Acid SCHEMBL15646089 | 0.91 | CA1 (0.43) | — | |
| Fumaric Acid SCHEMBL105086 | 0.91 | CA1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110366597-B | Blood profiling with protease inhibitors | 善威生物私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240060997-A1 | Blood Preparation and Profiling | SANGUI BIO PTY LTD (AU) | 2024-02-22 | — | — | US | disclosed |
| US-11693006-B2 | Blood profiling with protease inhibitors | SANGUI BIO PTY. LTD (AU) | 2023-07-04 | — | — | US | disclosed |
| EP-4009047-A1 | BLOOD PREPARATION AND PROFILING | Sangui Bio Pty. Ltd (AU) | 2022-06-08 | — | — | EP | disclosed |
| CN-114019171-A | Blood preparation and profiling | 善威生物私人有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11243218-B2 | Blood preparation and profiling | Sangui Bio Pty Ltd. (AU) | 2022-02-08 | — | — | US | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-108434126-B | Dry powder formulations and methods for treating pulmonary diseases | 普马特里克斯营业公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3359962-B1 | BLOOD PREPARATION AND PROFILING | SANGUI BIO PTY LTD (AU) | 2021-11-17 | — | — | EP | disclosed |
| EP-3470057-B1 | CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT | PULMATRIX OPERATING CO INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20150136130-A1 | INHALABLE DRY POWDERS | PULMATRIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20130243828-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130213398-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX OPERATING COMPANY, INC. | 2013-08-22 | — | — | US | disclosed |
| EP-2621488-A1 | CATIONIC DRY POWDERS | Pulmatrix, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2611438-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012050945-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120064126-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2012030664-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-2410981-A2 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111680-A2 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |